NetWorth
LeaderPortfolio
Yi
Zhu Yi
Rank #353
CHINA•Healthcare•Pharmaceuticals

Zhu Yi

Net Worth
$9.664B
+4.54% (24h)
Zhu Yi is the Chairman of Biokin Pharmaceutical, a company specializing in the development of pharmaceuticals, including cancer treatments, anesthesia injections, and traditional Chinese medicine. His estimated net worth is $11.57 billion, placing him among the wealthiest individuals globally. Zhu's career includes a background in academia, where he taught immunology and microbiology. He founded Biokin Pharmaceutical in 1996, and the company went public in Shanghai in 2023. Zhu holds advanced degrees from Fudan University and Sichuan University. His achievements include establishing a Seattle-based subsidiary, SystImmune, and leading the company's significant partnership with Bristol Myers Squibb. Zhu is committed to expanding Biokin globally.

How to read Zhu Yi's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Zhu Yi, we anchor the narrative to Pharmaceuticals and Pharmaceuticals, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $9.664B alongside global rank #353, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (CHINA) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life and Education

Zhu Yi, a prominent figure in the pharmaceutical industry, was born in the 1960s in a factory town in Neijiang, Sichuan. He showed academic promise early on, drawing inspiration from figures like Albert Einstein and the national push for scientific advancement in China. He initially aspired to become a scientist. Zhu graduated with a biophysics degree from Fudan University and later pursued advanced studies, earning a doctorate in management from Sichuan University. Prior to his entrepreneurial ventures, Zhu taught immunology and microbiology at West China Medical University from 1987 to 1990. His academic background provided a solid foundation for his later success in the pharmaceutical sector.

Rise to Success

In 1996, Zhu Yi founded Sichuan Biokin Pharmaceutical, later known as Biokin Pharmaceutical. The company initially focused on generic drugs, with its ribavirin granule brand becoming a domestic bestseller. The profits from these ventures were then strategically invested to support Biokin's expansion into innovative drug development. Zhu's leadership has been instrumental in driving Biokin's growth. The company went public in Shanghai in 2023, raising $136 million. He also established a subsidiary in Seattle, SystImmune, which focuses on cancer drug development.

Key Business Strategies

Zhu Yi's strategy involves a blend of innovation and strategic partnerships. He has been focused on developing innovative cancer treatments and expanding its global presence. A significant milestone includes Biokin's strategic partnership with Bristol Myers Squibb (BMS), valued at $8.4 billion, for the joint development and commercialization of a potential cancer treatment. This deal underscores Biokin's capabilities in the field. Zhu's work ethic is also worth noting; he often works seven days a week.

Philanthropy

Information regarding Zhu Yi's specific philanthropic initiatives and amounts is not available in the search results. However, it is likely that with his wealth and the nature of his industry, he is involved in supporting healthcare-related causes. Details of his philanthropic efforts are not widely publicized but can be confirmed when available.

Career Timeline

2023

Bristol Myers Squibb Deal

Oversaw a strategic partnership with Bristol Myers Squibb for $8.4 billion.

2023

Biokin IPO

Led Biokin Pharmaceutical's successful IPO in Shanghai, raising $136 million.

1987-1990

Lecturer

Taught immunology and microbiology at West China Medical University.

1996

Founded Biokin Pharmaceutical

Established Biokin Pharmaceutical, focusing on generic drugs, which later transitioned to innovative drug development.

Key Business Ventures & Holdings

CompanyStakeValue
Baili Pharmaceutical74.34%—

Net Worth History

In-Depth Analysis

Early Life and Education

Zhu Yi, a prominent figure in the pharmaceutical industry, was born in the 1960s in a factory town in Neijiang, Sichuan. He showed academic promise early on, drawing inspiration from figures like Albert Einstein and the national push for scientific advancement in China. He initially aspired to become a scientist. Zhu graduated with a biophysics degree from Fudan University and later pursued advanced studies, earning a doctorate in management from Sichuan University. Prior to his entrepreneurial ventures, Zhu taught immunology and microbiology at West China Medical University from 1987 to 1990. His academic background provided a solid foundation for his later success in the pharmaceutical sector.

Rise to Success

In 1996, Zhu Yi founded Sichuan Biokin Pharmaceutical, later known as Biokin Pharmaceutical. The company initially focused on generic drugs, with its ribavirin granule brand becoming a domestic bestseller. The profits from these ventures were then strategically invested to support Biokin's expansion into innovative drug development. Zhu's leadership has been instrumental in driving Biokin's growth. The company went public in Shanghai in 2023, raising $136 million. He also established a subsidiary in Seattle, SystImmune, which focuses on cancer drug development.

Key Business Strategies

Zhu Yi's strategy involves a blend of innovation and strategic partnerships. He has been focused on developing innovative cancer treatments and expanding its global presence. A significant milestone includes Biokin's strategic partnership with Bristol Myers Squibb (BMS), valued at $8.4 billion, for the joint development and commercialization of a potential cancer treatment. This deal underscores Biokin's capabilities in the field. Zhu's work ethic is also worth noting; he often works seven days a week.

Philanthropy

Information regarding Zhu Yi's specific philanthropic initiatives and amounts is not available in the search results. However, it is likely that with his wealth and the nature of his industry, he is involved in supporting healthcare-related causes. Details of his philanthropic efforts are not widely publicized but can be confirmed when available.

Data Sources & Methodology

Figures for Zhu Yi are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom